Back to Search Start Over

Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study

Authors :
Kenet, Gili
Kirkham, Fenella
Niederstadt, Thomas
Heinecke, Achim
Saunders, Dawn
Stoll, Monika
Brenner, Benjamin
Bidlingmaier, Christoph
Heller, Christine
Knöfler, Ralf
Schobess, Rosemarie
Zieger, Barbara
Sébire, Guillaume
Nowak-Göttl, Ulrike
Knöfler, Ralf
Sébire, Guillaume
Nowak-Göttl, Ulrike
European Thromboses Study Group
Source :
Lancet Neurology. Jul2007, Vol. 6 Issue 7, p595-603. 9p.
Publication Year :
2007

Abstract

Summary: Background: The relative importance of previous diagnosis and hereditary prothrombotic risk factors for cerebral venous thrombosis (CVT) in children in determining risk of a second cerebral or systemic venous thrombosis (VT), compared with other clinical, neuroimaging, and treatment variables, is unknown. Methods: We followed up the survivors of 396 consecutively enrolled patients with CVT, aged newborn to 18 years (median 5·2 years) for a median of 36 months (maximum 85 months). In accordance with international treatment guidelines, 250 children (65%) received acute anticoagulation with unfractionated heparin or low-molecular weight heparin, followed by secondary anticoagulation prophylaxis with low-molecular weight heparin or warfarin in 165 (43%). Results: Of 396 children enrolled, 12 died immediately and 22 (6%) had recurrent VT (13 cerebral; 3%) at a median of 6 months (range 0·1–85). Repeat venous imaging was available in 266 children. Recurrent VT only occurred in children whose first CVT was diagnosed after age 2 years; the underlying medical condition had no effect. In Cox regression analyses, non-administration of anticoagulant before relapse (hazard ratio [HR] 11·2 95% CI 3·4–37·0; p<0·0001), persistent occlusion on repeat venous imaging (4·1, 1·1–14·8; p=0·032), and heterozygosity for the G20210A mutation in factor II (4·3, 1·1–16·2; p=0·034) were independently associated with recurrent VT. Among patients who had recurrent VT, 70% (15) occurred within the 6 months after onset. Conclusion: Age at CVT onset, non-administration of anticoagulation, persistent venous occlusion, and presence of G20210A mutation in factor II predict recurrent VT in children. Secondary prophylactic anticoagulation should be given on a patient-to-patient basis in children with newly identified CVT and at high risk of recurrent VT. Factors that affect recanalisation need further research. [Copyright &y& Elsevier]

Details

Language :
English
ISSN :
14744422
Volume :
6
Issue :
7
Database :
Academic Search Index
Journal :
Lancet Neurology
Publication Type :
Academic Journal
Accession number :
25491294
Full Text :
https://doi.org/10.1016/S1474-4422(07)70131-X